Evoke Pharma Inc Cash Flow-to-Debt Ratio
Evoke Pharma Inc cash flow-to-debt ratio. Evoke Pharma Inc (EVOK) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of $-521.96K could theoretically repay 0% of its total liabilities ($12.29 Million) in one year. See financial agility of Evoke Pharma Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Evoke Pharma Inc (2011–2024)
Cash flow-to-debt ratio of Evoke Pharma Inc from 2011 to 2024. Historical debt coverage capacity for Evoke Pharma Inc across 14 annual periods. Also explore Evoke Pharma Inc net asset momentum to track the company's year-over-year net asset growth rate.
Evoke Pharma Inc Cash Flow-to-Debt Ratio by Year (2011–2024)
Evoke Pharma Inc cash flow-to-debt ratio by year from 2011 to 2024. Year-by-year debt coverage analysis for Evoke Pharma Inc. For the full cash flow conversion analysis, see EVOK cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.52x | $-5.46 Million | $10.48 Million | ▼ -0.8% |
| 2023 | -0.52x | $-4.98 Million | $9.65 Million | ▲ +39.2% |
| 2022 | -0.85x | $-6.60 Million | $7.77 Million | ▲ +51.8% |
| 2021 | -1.76x | $-12.35 Million | $7.02 Million | ▼ -235.8% |
| 2020 | -0.52x | $-6.63 Million | $12.65 Million | ▲ +81.7% |
| 2019 | -2.86x | $-5.76 Million | $2.02 Million | ▲ +33.0% |
| 2018 | -4.27x | $-6.98 Million | $1.63 Million | ▼ -182.9% |
| 2017 | -1.51x | $-8.72 Million | $5.78 Million | ▲ +4.6% |
| 2016 | -1.58x | $-8.71 Million | $5.51 Million | ▲ +8.6% |
| 2015 | -1.73x | $-10.50 Million | $6.07 Million | ▲ +8.1% |
| 2014 | -1.88x | $-11.50 Million | $6.11 Million | ▼ -135.4% |
| 2013 | -0.80x | $-3.04 Million | $3.80 Million | ▼ -803.4% |
| 2012 | -0.09x | $-1.75 Million | $19.78 Million | ▲ +43.2% |
| 2011 | -0.16x | $-2.89 Million | $18.56 Million | — |